Novo Nordisk Annual Report 2021

Contents Introducing Novo Nordisk Strategic Aspirations Key risks Management Consolidated statements Additional information Novo Nordisk Annual Report 2021 97 2022 financial calender 24 March 2022 Annual General meeting Į 28 March 2022 Record date 5 April 2022 Payment, ADRs 4 August 2022 Financial statement for the first six months of 2022 15 August 2022 Record date 23 August 2022 Payment, ADRs 25 March 2022 Ex-dividend 29 March 2022 Payment, B shares 4 May 2022 Financial statement for the first three months of 2022 12 August 2022 Ex-dividend 16 August 2022 Payment, B shares 1 February 2023 Financial statement for 2022 and Annual Report 2022 2 November 2022 Financial statement for the first nine months of 2022 Product overview Diabetes care New-generation insulin and combinations Tresiba, insulin degludec RyzodegⓇ 70/30, insulin degludec/insulin Xultophy, insulin degludec/liraglutide aspart Fiasp, fast-acting insulin aspart Modern insulin. Levemir, insulin detemir NovoRapid**, insulin aspart NovoMix 30, biphasic insulin aspart NovoMix® 50, biphasic insulin aspart NovoMix 70, biphasic insulin aspart Human insulin Insulatard®, isophane (NPH) insulin Actrapid, regular human insulin Mixtard 30, biphasic human insulin Mixtard® 40, biphasic human insulin Mixtard® 50, biphasic human insulin Glucagon-like peptide-1 Victoza, liraglutide Ozempic, semaglutide Rybelsus, oral semaglutide Pre-filled delivery system FlexTouch®, U100, U200 FlexPen® InnoLetⓇ Ozempic® pen OzempicⓇ Single dose device Durable delivery systems NovoPen® 6 NovoPen® 5 NovoPen 4 NovoPen Echo® Plus NovoPen Echo® Other delivery systems PumpCart, NovoRapid® & Fiasp® cartridge to be used in pump Cartridge Vial Oral antidiabetic agents Novo Norm, repaglinide Glucagon GlucaGen®, glucagon for diagnostic use GlucaGen® Hypokit, glucagon emergency kit for severe hypoglycaemia Needles NovoFine Plus NovoFine® NovoTwistⓇ NovoFine® AutoCoverⓇ Obesity care Glucagon-like peptide-1 Saxenda, liraglutide 3.0 mg Wegovy, semaglutide 2.4 mg, FlexTouch® Obesity delivery systems Saxenda pen Wegovy, Single dose device, FlexTouch® Biopharm Rare Blood Disorders NovoSeven, recombinant factor VIIa, also available with pre-filled syringe in an increasing number of countries NovoEight®***, recombinant factor VIII NovoThirteen, recombinant factor XIII Refixia®****, nonacog beta pegol; N9-GP Esperoct, turoctocog alfa pegol, NS-GP Rare Endocrine Disorders Norditropin, somatropin (rDNA origin) Sogroya, somapacitan Macrilen™, macimorelin; growth hormone secretagogue receptor agonist Human growth hormone delivery system Pre-filled delivery system FlexProⓇ NordiFlex® Nordilet® NordiPenⓇ Durable delivery systems Durable multi-dose delivery system to be used with Norditropin® SimpleXx® * In the US approved under the brand name Xultophy® 100/3.6 ** In the US called NovoLog® *** In the US spelt Novoeight **** In the US approved under the name of REBINYN® Other delivery system PenMate, automatic needle inserter (for NordiPen and NordiFlex®) Hormone replacement therapy Vagifem, estradiol hemihydrate Activelle, estradiol/norethisterone acetate Kliogest, estradiol/norethisterone acetate NovofemⓇ, estradiol/norethisterone acetate Trisequens, estradiol/norethisterone acetate Estrofem, estradiol

View entire presentation